Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2025-04-03 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement related to previously published announcements about the change and reappointment of an accounting firm. It details corrections to the integrity records of the accounting firm and its personnel, including regulatory penalties and disciplinary actions. The document does not contain financial statements or detailed financial data but rather corrects information in prior announcements. The document length is 3006 characters, which is relatively short and consistent with an announcement rather than a full report. The content is focused on correcting disclosures about the accounting firm, which aligns with a regulatory or compliance announcement rather than a full audit report or annual report. Therefore, this document fits best under Regulatory Filings (RNS) as it is a correction announcement that does not constitute a full audit report or financial report itself.
2025-04-03 Chinese
关于实际控制人股份质押和解除质押的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding the pledge and release of shares by the company's actual controller, including detailed tables of shareholding and pledge status. It is a disclosure about share pledging activities by major shareholders, not a financial report or management discussion. The document is short (1884 characters) and focuses on share pledge information, which fits the category of Major Shareholding Notification (MRQ). There is no indication of it being an annual report, earnings release, or other financial report. Therefore, the appropriate classification is MRQ.
2025-04-02 Chinese
关于全资子公司为上市公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 瑞康医药集团股份有限公司 regarding its wholly-owned subsidiaries providing guarantees for the listed company. It includes details about credit limits, internal approvals, financial data summaries, and compliance with regulatory requirements. The document does not contain a full financial report or detailed financial statements but rather focuses on a specific financing guarantee event and related disclosures. The length is about 2290 characters, which is relatively short and typical for an announcement. There is no indication that this is a full annual or interim report, audit report, or earnings release. The content fits the description of a Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by subsidiaries to support credit facilities.
2025-03-24 Chinese
关于全资子公司为上市公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 瑞康医药集团股份有限公司 regarding its wholly-owned subsidiaries providing guarantees for the listed company. It includes details about credit limits, internal approvals, financial data summaries, and compliance with regulatory requirements. The document is relatively short (2306 characters) and focuses on a specific financing guarantee event rather than presenting comprehensive financial statements or detailed financial performance. It does not contain full financial reports or earnings data but rather an update on financing-related guarantees and approvals. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-03-05 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, prices, total amount spent, compliance with regulatory rules, and future plans for the repurchase. It does not contain financial statements or detailed financial analysis but is a regulatory disclosure about share buyback activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on share repurchase progress, confirming it is not a full financial report or other type of filing.
2025-03-04 Chinese
估值提升计划
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a listed company about its 'Valuation Enhancement Plan' triggered by the stock price being below net asset value for 12 consecutive months, as per regulatory guidance. It includes descriptions of business strategies, cash dividends, share repurchase plans, and investor relations management. The document references board meeting approvals and contains no financial statements or quarterly/yearly financial results. It is not an earnings release, annual report, or interim report. It is a regulatory announcement about a corporate plan related to capital management and shareholder value enhancement, including share repurchase details. Given the content and length (3339 characters), it is not a full financial report but a regulatory announcement about capital and financing activities. Therefore, the best fitting category is Capital/Financing Update (CAP).
2025-02-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.